The US Agency for International Development (USAID) and the US President’s Emergency Plan for AIDS Relief (PEPFAR) announced they have secured a 30% price reduction on the TB preventive treatment regimen called 3HP (combining two drugs – rifapentine and isoniazid), taking the price from $14.25 to $9.99 for a three-month patient course. This lower price will be available through the Stop TB Partnership’s Global Drug Facility.
USAID and PEPFAR have committed to spending a combined $25 million to provide 3HP to 2.5 million people at risk of TB around the world, covering 750,000 more people than would have previously been reached at higher prices. Furthermore, USAID has made moves toward making access more sustainable in low- and middle-income countries by developing a more efficient, cheaper way to produce the base ingredients of rifapentine. USAID is now facilitating a technology transfer of this new method to a local manufacturer in Africa.
SEE ALSO:
For more TB news, check out the latest edition of the TB Online Weekly Newsletter (#29, 28 September 2023) providing full coverage of the UN General Assembly High-Level Meeting on TB, held on 22 September 2023.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.